Suppliers and packagers for generic pharmaceutical drug: letermovir

letermovir

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Msd	PREVYMIS	letermovir	PELLETS;ORAL	219104	NDA	Merck Sharp & Dohme LLC	0006-5085-01	30 PACKET in 1 CARTON (0006-5085-01) / 48 PELLET in 1 PACKET	2024-08-30
Msd	PREVYMIS	letermovir	PELLETS;ORAL	219104	NDA	Merck Sharp & Dohme LLC	0006-5086-01	30 PACKET in 1 CARTON (0006-5086-01) / 8 PELLET in 1 PACKET	2024-08-30
Merck Sharp Dohme	PREVYMIS	letermovir	SOLUTION;INTRAVENOUS	209940	NDA	Merck Sharp & Dohme LLC	0006-5003-01	1 VIAL, SINGLE-DOSE in 1 CARTON (0006-5003-01) / 12 mL in 1 VIAL, SINGLE-DOSE (0006-5003-02)	2017-11-08

Last updated: July 29, 2025

ppliers for the Pharmaceutical Drug: LETERMOVIR

Introduction
Letermovir (formerly known by its developmental code, MVL-1501) is an investigational antiviral agent primarily designed to prevent cytomegalovirus (CMV) infections in immunocompromised patients, including transplant recipients and individuals with HIV/AIDS. As an emerging therapeutic, understanding the landscape of suppliers for letermovir is essential for stakeholders involved in healthcare procurement, investment, and pharmaceutical manufacturing. This report delineates current suppliers, manufacturing sources, and the broader supply chain considerations for letermovir, offering insights into its commercial and R&D trajectory.

Development and Approval Context
Letermovir is developed by Merck & Co., Inc. (known as MSD outside North America). The drug received approval from the U.S. Food and Drug Administration (FDA) in November 2017 under the brand name Letermovir for CMV prophylaxis in stem cell transplant recipients.[1] Regulatory approvals in other jurisdictions, such as the European Medicines Agency (EMA), follow similar timelines, contingent upon data demonstrating safety and efficacy.

Manufacturing and Supply Chain Overview

Manufacturing Origin and Primary Suppliers

The production of letermovir involves complex synthesis processes typical of antiviral agents, requiring high-purity chemical intermediates and sophisticated pharmaceutical manufacturing facilities. As of the latest available information, Merck owns or licenses the manufacturing rights for key APIs and formulations, emphasizing vertical integration to ensure quality and supply stability.

Active Pharmaceutical Ingredient (API) Suppliers

While Merck develops and controls the synthesis pathway internally, it is common for pharmaceutical companies to source APIs from specialized manufacturing entities. Currently, there is limited public disclosure regarding the exact API suppliers for letermovir, which is typical for proprietary products. However, industry analysts suggest that Merck likely collaborates with qualified CDMO (Contract Development and Manufacturing Organization) partners, possibly located in Asia (e.g., China, India) or Europe, to ensure robust supply chains and cost efficiencies.

Formulation and Packaging Suppliers

The finished product, available as oral capsules, involves formulation suppliers that specialize in capsule filling, coating, and packaging. Merck’s global supply chain likely incorporates third-party packaging firms at various regional hubs to facilitate distribution in North America, Europe, and emerging markets.

Distribution and Logistics

Post-manufacturing, letermovir's distribution depends on licensed channels overseen by Merck’s global logistics network. The company maintains strategic partnerships with logistics providers to ensure cold chain integrity, regulatory compliance, and timely delivery to healthcare providers.

Key Suppliers in the Pharmaceutical Ecosystem

Contract Manufacturing Organizations (CMOs)

Given Merck's focus on quality and scalability, several CMOs potentially involved in letermovir’s production include prominent global players such as Lonza, Catalent, and Patheon (a part of Thermo Fisher Scientific). These organizations are known for high-containment chemical synthesis, sterile manufacturing, and formulation development—crucial for antiviral drugs with complex synthesis routes.

Chemical Intermediates and Specialty Chemical Suppliers

Suppliers providing specialty chemicals—such as chiral building blocks, heterocyclic compounds, and high-grade solvents—are vital to the synthesis process. While specific suppliers remain confidential, major chemical suppliers like BASF, DSM, and Evonik are typically involved in supplying raw materials for antiviral APIs.

Packaging Material Suppliers

Suppliers like Gerresheimer and West Pharmaceutical Services provide pharmaceutical-grade capsules, blisters, and container-closures systems essential in maintaining API stability and ensuring patient safety.[2]

Supply Chain Challenges and Considerations

Intellectual Property and Licensing Agreements

Despite Merck’s control over letermovir, patent protections and licensing agreements influence the supply landscape. Licensing partnerships in emerging markets can impact access and manufacturing rights, influencing the diversity of suppliers involved.

Manufacturing Complexity and Scalability

The bespoke synthesis process for letermovir involves multiple steps, creating challenges related to scalability, cost, and quality assurance. Scaling production from clinical to commercial batches requires validated processes, which some suppliers may not have initially established.

Regulatory and Geopolitical Risks

Global supply chains are susceptible to geopolitical tensions, trade restrictions, and regulatory updates. Disruptions in key manufacturing regions, especially in Asia, could impact production timelines and supply stability.

Emerging Trends and Future Outlook

Supply Chain Diversification

To mitigate risks, Merck and other industry players are increasingly adopting supply chain diversification, engaging multiple suppliers for APIs and formulation components. This strategy enhances resilience against disruptions.

Innovation and Contract Partnerships

The trend toward strategic alliances with biotech and chemical manufacturers enables faster scale-up and adaptation to demand shifts. For letermovir, partnerships with emerging CDMOs could lower costs and accelerate availability.

Potential Biosimilar and Generic Competition

Although no biosimilar or generic version currently exists for letermovir, patent expiry or licensing modifications might invite new entrants, expanding the supplier base over time.

Conclusion
The suppliers for letermovir are predominantly controlled by Merck, with key inputs sourced from specialized chemical and pharmaceutical manufacturing organizations. The supply chain's sophistication, involving complex synthesis processes, necessitates strategic partnerships, contract manufacturing, and rigorous quality assurance. As letermovir’s market penetration expands, supply chain resilience, diversification, and regulatory compliance will dictate its availability and pricing dynamics.

---

Key Takeaways

• Merck predominantly manages letermovir’s manufacturing, sourcing APIs and formulation components through global CDMOs and chemical suppliers.
• Ensuring supply chain resilience involves diversification across multiple regional suppliers and manufacturing partners.
• The complexity of antiviral synthesis imposes scalability challenges, requiring ongoing investment in manufacturing validation.
• Regulatory considerations and geopolitical tensions significantly influence supply chain stability, necessitating proactive risk management.
• Future market expansion and patent considerations may alter supplier dynamics, potentially inviting new entrants and generic competitors.

---

FAQs

Q1: Who are the main inventors or originators of letermovir’s API?
A: The API for letermovir was developed by Merck & Co., with proprietary synthesis routes kept confidential but likely involving chemical suppliers and CDMOs specializing in complex antiviral APIs.

Q2: Are there alternative suppliers for letermovir’s active ingredients in case of shortages?
A: Currently, Merck maintains tight control over supplier relationships, but the industry trend toward diversification suggests the potential for multiple sources as demand grows.

Q3: What regions are primary sources of raw materials and manufacturing for letermovir?
A: Major sources include North America and Europe for formulation, with API synthesis potentially involving suppliers in Asia (China, India) due to cost and manufacturing capacity advantages.

Q4: How does supply chain complexity impact letermovir’s market availability?
A: The complex synthesis and formulation processes necessitate rigorous quality control; disruptions can lead to shortages, emphasizing the importance of diversified sourcing and contingency planning.

Q5: What future developments could influence the supplier landscape for letermovir?
A: Patent expirations, biosimilar development, and licensing agreements might expand or alter the supplier ecosystem, affecting pricing, availability, and regional access.

---

Sources:
[1] FDA. (2017). "FDA Approves New Drug for Prevention of Cytomegalovirus in Transplant Patients."
[2] West Pharmaceutical Services. (2022). “Pharmaceutical Packaging Materials and Systems.”